Physician profile
Rashmi Sanjay
NPI 1205869948
$8,609.19
in general payments reported to CMS, 2019-2025
64 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,853 · 2020: $804 · 2021: $49.05 · 2023: $116 · 2024: $2,162 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028 · Consulting Fee: $1,850 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.76 |
| Consulting Fee | $1,850.00 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,355.22 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $941.35 | 2020-2025 | Vanflyta, Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $809.24 | 2019-2025 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Pfizer INC. | $384.55 | 2019-2025 | |
| Genentech USA, INC. | $328.89 | 2019-2025 | Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $268.68 | 2019-2025 | Opdivo |
| Eisai INC. | $266.87 | 2019-2025 | |
| Janssen Biotech, INC. | $197.95 | 2019-2025 | Talvey, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $192.01 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Seagen INC. | $191.71 | 2019-2020 | |
| Incyte Corporation | $190.34 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $170.98 | 2019-2025 | Reblozyl |
| Gilead Sciences, INC. | $170.90 | 2021-2025 | Trodelvy |
| Abbvie INC. | $151.22 | 2024-2025 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Sanjay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.